

S4 Table. Best responses for the first-line atezolizumab plus bevacizumab treatment

	Total (n=246)	Short-term treatment group ^{a)} (n=177)	Long-term treatment group ^{b)} (n=69)	p-value ^{c)}
Best response, n (%)				< 0.001
CR	11 (4.5)	2 (1.1)	9 (13.0)	
PR	68 (27.6)	25 (14.1)	43 (62.3)	
SD	114 (46.3)	97 (54.8)	17 (24.6)	
PD	53 (21.5)	53 (29.9)	0	
Objective response rate (%)	32.1	15.3	75.4	< 0.001

CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease. ^{a)}Patients treated with atezolizumab plus bevacizumab for less than 1 year, ^{b)} Patients treated with atezolizumab plus bevacizumab for 1 year or more, ^{c)} Fisher's exact test or Pearson's chi-square test, as appropriate.